Professor Molly Shoichet awarded the Gerzhard Herzberg Canada Gold Medal

   Media Coverage
SCIENCE hydrogels ROBERTA BAKER molly schoichet web

Professor Molly Shoichet, co-founder of AmacaThera and a University of Toronto Professor in the Department of Chemical Engineering & Applied Chemistry, has received the Gerhard Herzberg Canada Gold medal.

She was recently featured in an interview by Mohammad Haddahnia with The Varsity, the University of Toronto’s student newspaper. According to the article, the prestigious Canadian science award recognizes her outstanding accomplishments and discoveries, and for her advancement of scientific knowledge and innovation,” specifically in regenerative medicine.

Shoichet’s work in synthetic hydrogel materials led to AmacaThera’s formation as a biotechnology company in 2016.

Here’s an excerpt: 

Shoichet is an internationally known researcher for her innovative use of three-dimensional hydrogels in the field of tissue engineering. Hydrogels are essentially water-swollen materials and are found everywhere — from the food that we eat to the contact lenses that we wear.

Hydrogels are also used as scaffolds for tissue engineering. These scaffolding hydrogels contain large pores to accommodate living cells. They can also be designed to dissolve or degrade, releasing chemicals to encourage cell growth and allowing the cells to proliferate in the pores.

Shoichet and her team use hydrogels as biomimetic materials and have invented a series of hydrogels. One hydrogel that we invented promotes tissue healing while serving as a vehicle for cell transplantation and therapeutic delivery,” wrote Shoichet. This material is being advanced towards the clinic for the treatment of post-surgical pain by AmacaThera.”

AmacaThera is a U of T startup that was built on the technologies developed in Shoichet’s lab.

Read the full interview.

More Recent News

AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care

   Press Release

AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more

New study setting the stage for non-opioid analgesic in post-surgical pain management

   Press Release

AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more

AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform

   Press Release

AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more

Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Contact Us

MaRS Centre, West Tower,
661 University Ave Suite 1300,
Toronto, ON M5G 0B7

[email protected]